

NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
MARCH 15, 2011

CALL TO ORDER / ANNOUNCEMENTS

The NCI-Frederick Institutional Biosafety Committee was convened at 12:05 p.m. in Building 549 Meeting Room B with the following members in attendance:

Voting

- | | |
|---|--|
| <input type="checkbox"/> Michael Baseler (regrets) | <input checked="" type="checkbox"/> Scott Jendrek |
| <input checked="" type="checkbox"/> Theresa Bell | <input type="checkbox"/> Serguei Kozlov (regrets) |
| <input type="checkbox"/> Stephen Creekmore (regrets) | <input checked="" type="checkbox"/> Dan McVicar (Chair) |
| <input checked="" type="checkbox"/> Bruce Crise | <input checked="" type="checkbox"/> Randall Morin |
| <input checked="" type="checkbox"/> Eric Freed | <input checked="" type="checkbox"/> Shalini Oberdoerffer |
| <input type="checkbox"/> Melinda Hollingshead (regrets) | <input checked="" type="checkbox"/> Raja Sriperumbudur |
| <input checked="" type="checkbox"/> Stephen Hughes | <input checked="" type="checkbox"/> Lucien Winegar |
| <input checked="" type="checkbox"/> Sarah Hooper | <input checked="" type="checkbox"/> Rev. David Betzner |

Non-Voting

- Walter Hubert
- Kim DiGiandomenico

Sarah Hooper was introduced to the committee as the OHS representative on the IBC in replacement of Alberta Peugeot.

APPROVAL OF MINUTES FROM FEBRUARY 15, 2011 MEETING

The February 15, 2011 meeting minutes were approved as written.
(A motion and second were made. (For: (12) Against: (0) Abstain: (0))

ACCIDENT REVIEWS – none to report

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

Serguei Kozlov 11-11: Establishing procedures for derivation of induced pluripotent stem cells (iPSC) from cancer GEM models for the purpose of increasing the capacity of preclinical drug development This group will be using mouse fibroblasts and infecting them with Adenoviral vectors to turn them back into embryonic stem cells. One construct will be using the *myc* oncogene; however the PI sufficiently addressed the safety and handling hazards in his protocol. Additionally, cells will not be harvested until after 6-7 passages. For clarity, the IBC has asked the PI to indicate in the registry if the company provides any information regarding the amount of replication-competent virus in the stocks (B5e2) and also wanted the PI to add to his handling protocol that prior to removal from the BSC, all tubes will be decontaminated. Dan McVicar moved to approve the registry with the additional clarifications. Scott Jendrek seconded the motion. (For: 12 Against: 0 Abstain: 0)

P. Charles Lin 11-13: Vascular Biology in Cancer The research in this laboratory centers on the mechanisms that govern blood vessel formation (angiogenesis) and vascular homeostasis in cancer. The committee had difficulty determining what the proposed experiments would be, how mouse stem cells would be used, and had noted that the Adeno-Cre experiments outlined in the IBC were not included in

**NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE**

the ASP. Bruce Crise offered to assist the PI with the committee's specific concerns and motioned to defer the registry until more information was received. Steve Hughes seconded the motion. (For deferral: 12 Against: 0 Abstain: 0)

Chih-Jian (Jason) Lih / Mickey Williams 11-14: *Extraction of nucleic acid from FFPE tissues* This registry is for a new group who is dedicated to develop clinical assays for diagnostic purposes. The clinical assays will include profiling of gene expression by microarray and mutation detection by next generation sequencing. The lab procedure associated with this proposal is nucleic acid extraction of clinical tissues. Overall the registry was well written after pre-review; however the committee wanted the SOPs to be less protocol-driven and more explicit regarding safety of the materials at the various stages of handling. More specifically the IBC wanted to know what was in the lysis buffer and how it could inactivate enveloped and non-enveloped viruses that could be in the samples being processed. The committee asked for the SOP to be related more to the techniques being used also. For instance, how are fixed samples manipulated as opposed to unfixed samples or are they all treated equally? Are the unfixed samples known to be free of specific pathogens (ex. snap frozen tissues, whole blood)? In addition, the PI needed to identify what detergent/disinfectant would be used for decontamination of liquids and surfaces at the end of experiments or in the event of a spill. Lastly, the PI should also discuss what to do in the event of an exposure. Eric Freed moved to conditionally approve the registry pending the aforementioned clarifications in the SOP. Scott Jendrek seconded the motion. (For: 12 Against: 0 Abstain: 0).

RENEWALS

Ira Daar / Deborah Morrison 11-12 (07-04): *Protooncogene Signal Transduction* This renewal is to continue work to examine the signaling pathways involved in morphogenetic events during development using a *Xenopus laevis* model system and also mammalian tissue culture. Lead reviewers also recommended for the PI and staff to take the viral vector safety training. Shalini Oberdoerffer moved to approve the registry. Dan McVicar seconded the motion. (For: 12 Against: 0 Abstain: 0)

Michael Kuehn 11-15 (06-102): *Analysis of targeted mutations in mice* Using knock-out and knock-in animals, the objectives of this renewal registry are to identify and analyze genes that play a critical role in mouse embryonic development. The committee requested clarification for the types of sharps that will be employed in the studies. They also recommended for the cartons used to transport GEM animals between buildings to be taped closed as an additional precaution should the container be dropped. Steve Hughes moved to approve the registry pending clarifications requested above. Raja Sriperumbudur seconded the motion. (For: 12 Against: 0 Abstain: 0)

OUTSTANDING ITEMS

Jeff Lifson 11-09 (P200704JLA01): *Pathogenesis and immunological control of human and non-human primate retroviruses* – waiting on clarifications from PI post February IBC meeting so that approval can be released

Patricia Steeg / Joji Nakayama 11-02: *Examination of effects of loss of LPA1 mediated signal in MDA-MB-231T xenograft model* – waiting for correspondence from Jean Claude Marshall regarding experiment feasibility

Trinchieri/Noer – IBC 10-60 *Flow cytometry core lab* – Dan McVicar is obtaining a more comprehensive list of cell types from Kathleen Noer and then the group plans to meet with Michael Baseler to further discuss handling options.

AMENDMENTS

Fifteen amendments were processed and approved between the February and March meetings.

**NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE**

OTHER BUSINESS

Theresa Bell informed the committee of a submission she received from the BDP just prior to the meeting to reconstitute Lipopolysaccharide (LPS) endotoxin with heavy water inside a biosafety cabinet. After much discussion, Bruce Crise motioned that the PI needs to supply the concentration and what the LD50 is. If the LD50 is less than 1/10 of the volume that they will have at one time, then no IBC registration is necessary. Lucien Winegar seconded the motion. (For: 11; Against: 0; Abstain: 1).

ADJOURNMENT

The meeting was adjourned at 1:00pm.

Next meetings:

April 19, 2011 (549 EBR)

May 17, 2011 (426CR)